See more : Braveheart Resources Inc. (RIINF) Income Statement Analysis – Financial Results
Complete financial analysis of Certara, Inc. (CERT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Certara, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Touax SCA (TOUP.PA) Income Statement Analysis – Financial Results
- Kogan.com Ltd (KGN.AX) Income Statement Analysis – Financial Results
- Federal Home Loan Mortgage Corporation (FMCCI) Income Statement Analysis – Financial Results
- NAGAWA Co., Ltd. (9663.T) Income Statement Analysis – Financial Results
- Inception Growth Acquisition Limited (IGTAR) Income Statement Analysis – Financial Results
Certara, Inc. (CERT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.certara.com
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 354.34M | 335.64M | 286.10M | 243.53M | 208.51M | 163.72M |
Cost of Revenue | 141.02M | 132.58M | 111.62M | 100.77M | 79.77M | 71.04M |
Gross Profit | 213.32M | 203.07M | 174.49M | 142.77M | 128.74M | 92.68M |
Gross Profit Ratio | 60.20% | 60.50% | 60.99% | 58.62% | 61.74% | 56.61% |
Research & Development | 34.17M | 28.21M | 20.38M | 19.64M | 11.63M | 10.48M |
General & Administrative | 95.39M | 71.77M | 79.54M | 88.48M | 47.93M | 43.39M |
Selling & Marketing | 32.02M | 27.41M | 20.14M | 19.20M | 10.73M | 9.42M |
SG&A | 127.41M | 99.18M | 99.68M | 107.68M | 58.66M | 52.81M |
Other Expenses | 92.51M | 43.16M | 40.85M | 39.86M | 38.84M | -107.00K |
Operating Expenses | 254.09M | 170.55M | 160.91M | 167.19M | 109.13M | 97.33M |
Cost & Expenses | 395.11M | 303.12M | 272.53M | 267.95M | 188.90M | 168.37M |
Interest Income | 0.00 | 17.77M | 16.84M | 25.30M | 28.00M | 0.00 |
Interest Expense | 22.92M | 17.77M | 16.84M | 25.30M | 28.00M | 27.80M |
Depreciation & Amortization | 56.07M | 52.47M | 45.12M | 42.75M | 41.56M | 37.01M |
EBITDA | 23.84M | 89.00M | 58.58M | 17.87M | 60.41M | 32.25M |
EBITDA Ratio | 6.73% | 26.52% | 20.47% | 7.34% | 28.97% | 19.70% |
Operating Income | -40.77M | 32.52M | 13.58M | -24.89M | 19.61M | -4.65M |
Operating Income Ratio | -11.51% | 9.69% | 4.75% | -10.22% | 9.41% | -2.84% |
Total Other Income/Expenses | -14.37M | -13.77M | -16.95M | -25.76M | -28.76M | -27.91M |
Income Before Tax | -55.14M | 18.76M | -3.38M | -50.18M | -9.15M | -32.56M |
Income Before Tax Ratio | -15.56% | 5.59% | -1.18% | -20.61% | -4.39% | -19.89% |
Income Tax Expense | 214.00K | 4.02M | 9.89M | -784.00K | -225.00K | 697.00K |
Net Income | -55.36M | 14.73M | -13.27M | -49.40M | -8.93M | -33.26M |
Net Income Ratio | -15.62% | 4.39% | -4.64% | -20.28% | -4.28% | -20.31% |
EPS | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
EPS Diluted | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
Weighted Avg Shares Out | 158.94M | 156.88M | 149.84M | 152.98M | 157.34M | 132.41M |
Weighted Avg Shares Out (Dil) | 158.94M | 159.35M | 149.84M | 152.98M | 157.34M | 132.41M |
Certara Reports First Quarter 2023 Financial Results
5 Must-Buy High-Flying Mid-Cap Stocks Ahead of Q1 Earnings
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
GSK's Jemperli Effective Against First-Line Endometrial Cancer
Are These 3 Small Momentum Stocks Setting Up Big Gains?
Best Momentum Stocks to Buy for March 15th
New Strong Buy Stocks for March 15th
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
Source: https://incomestatements.info
Category: Stock Reports